Therma Bright Receives Positive Notification From U.S. DHHS's Centers for Medicare & Medicaid (CMS)
Therma Bright Receives Positive Notification From U.S. DHHS's Centers for Medicare & Medicaid (CMS)
Company anticipates CMS permanent CPT(R) and HCPCS codes in the coming days
公司预计在未来几天内获得CMS永久的CPT(R)和HCPCS代码。
Toronto, Ontario--(Newsfile Corp. - August 1, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to provide a quick update from a recent notification from US Department of Health and Huma Services' (DHHS) Centers of Medicare and Medicaid (CMS). CMS has informed the Company of the pending permanent Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) codes for its Venowave VW5 device; anticipating notification and approval in the coming days.
多伦多,安大略省--(新闻稿--2014年8月1日)-- Therma Bright股份有限公司(TSXV:THRM)(OTCQB:TBRIF)(“Therma”或“公司”),是一家领先的、专有的诊断和医疗设备技术的开发商和投资伙伴,在最新的来自美国卫生与人类服务部(DHHS)医疗保险(CMS)的通知中,高兴地向大家提供快速的更新。CMS已通知公司其Venowave VW5设备的CPT和HCPCS代码正在审批中,并预计在未来几天内获得审批。
The CMS's CPT and HCPCS codes are expected to cover ten (10) health related and CMS reimbursable indications, which offers a great opportunity in the marketplace for the Company, its customers, reseller partners and shareholders. CMS will be publishing the final determinations for the 1st Biannual HCPCS Level II on this site: HCPCS Level II Coding Decisions.
CMS的CPT和HCPCS代码预计将涵盖十个与健康有关且可由CMS报销的适应症,为公司、客户、分销合作伙伴和股东提供了广阔的市场机会。CMS将在此网站上发布第一次半年度HCPCS二级编码的最终决定。
The ten (10) indications include:
这十个适应症包括:
- Prevention of deep vein thrombosis (DVT)
- Management of the symptoms of post-thrombotic syndrome (PTS)
- Prevention of primary thrombosis
- Treatment of lymphedema
- Diminishing post-operative pain and swelling
- Treatment of leg swelling due to vascular insufficiency
- Treatment of varicose veins
- Treatment of chronic venous insufficiency
- Enhancing blood circulation
- Treatment of intermittent claudication
- 预防深静脉血栓形成(DVT)
- 管理后血栓性综合症(PTS)症状
- 预防原发性血栓形成
- 淋巴水肿的治疗
- 缓解术后疼痛和肿胀
- 治疗由于血管功能不足引起的腿部肿胀
- 静脉曲张的治疗
- 治疗慢性静脉功能不全
- 增强血液循环
- 间歇性跛行的治疗
As shared in prior releases, the Centers for Disease Control and Prevention (CDC) estimates that over 900,000 U.S. citizens are impacted by deep vein thrombosis (DVT) and pulmonary embolism (PE) alone each year. And ResearchAndMarkets global research and MarketDigital research both projected the deep vein thrombosis global market alone to reach between USD $1.26 billion by 2028 and USD 1.554 billion by 2032, respectively.
正如之前发布的那样,疾病控制和预防中心(CDC)估计每年仅有超过900000名美国公民受到深静脉血栓形成(DVT)和肺栓塞(PE)的影响。ResearchAndMarkets全球研究和MarketDigital研究都预计,仅深静脉血栓形成的全球市场在2028年将达到约12.6亿美元,在2032年将达到约15.54亿美元。
"We're patiently awaiting confirmation from CMS, which is expected in a matter of days," shared Rob Fia, CEO of Therma Bright. "And we plan to make the announcement and all the details around the permanent codes immediately upon receipt of this formal approval."
“我们正耐心等待CMS的确认,预计将在几天内得到。” Therma Bright的CEO Rob Fia分享道:“我们计划在收到正式批准的通知后立即公布永久代码的所有细节以及公告。”
About Therma Bright Inc.
Therma Bright Inc.简介:Therma Bright是一家开发商和合作伙伴,在各种领先的专有诊断和医疗器械技术方面致力于为消费者和医疗专业人士提供质量卓越,创新的解决方案,以应对当今最重要的医疗和医疗保健挑战。在TSXV:THRM,OTCQB:TBRIF,FSE:JNX上交易。访问:。
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .
Therma Bright Inc.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on Twitter
Rob Fia,首席执行官
rfia@thermabright.com
rfia@thermabright.com
关注我们的Twitter账号
FORWARD-LOOKING STATEMENTS
前瞻性声明
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as the commercialization of Venowave, DCA, and InStatin, and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
本新闻稿中的某些声明构成“前瞻性”声明。这些声明涉及将来的事件,如在新闻稿中描述的商业化Venowave、DCA和InStatin以及相关技术。所有这类声明都涉及大量已知和未知的风险、不确定因素和其他因素,这可能导致实际结果与所述前瞻性声明所表达或所暗示的不同。前瞻性声明涉及重大风险和不确定性,它们不应被视为将来业绩或结果的保证,并不一定是这样结果的准确指标。实际结果可能因数个风险和因素而与预期结果存在差异。虽然本新闻稿中的前瞻性声明是在本新闻稿日期管理公司相信合理的假设基础上做出的,但公司不能保证投资者实际结果将与这些前瞻性声明一致。本新闻稿中的前瞻性声明是截至本文发布日期的,公司无意或有义务更新或修订这些前瞻性声明,除非适用的证券法规要求。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
TSX Venture Exchange及其监管服务提供商(如TSX Venture Exchange政策中所定义)对本新闻稿的充分性或准确性不承担责任。